Released Mar 5, 2019, after the close
10-K filed Mar 5, 2019, 64 days after period end · 0001564590-19-006258
Q4 2018 · 10-K
Revenue$1.66M$1.66M +61.7% vs Q4 2017+61.9% vs Q3 2018
Net Income-$16.03M-$16.03M N/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.25-$0.25 N/M vs Q4 2017N/M vs Q3 2018
Operating Incomederived-$16,741,000N/M
Operating Cash Flowderived-$11,020,000N/M
Free Cash Flowderived-$12,137,000N/M
Margins · derived
Operating margin-1007.9%+184.3 pt vs Q4 2017
Net margin-964.9%+251.9 pt vs Q4 2017
What the release said
The release
Same quarter
| Metric | Q4 2018 | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|---|
| Revenue | $1.66M | $1.03M | $1.03M | $1.08M |
| Net Income | -$16.03M | -$12.50M | -$7.94M | -$7.45M |
| EPS Diluted | -$0.25 | -$0.29 | -$0.21 | -$0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR